The Global Cancer Vaccine Market is Expected to Surpass $15 Billion by 2025 -- Personalized Cancer Vaccine: The Next Growth Frontier - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Global Cancer Vaccine Market & Clinical Trial Insight 2025” clinical trials has been added to ResearchAndMarkets.com’s offering.

The global cancer vaccine market opportunity is expected to surpass US$ 15 Billion by 2025.

In recent years, cancer vaccine segment as emerged as next growth frontier for the various stake holders involved in the research, development and commercialization of cancer therapeutics. The market for cancer therapeutics is growing at significant rates and it has already occupied a major share in the overall pharmaceutical market.

Vaccines have had a good reputation when it comes to their safety and therapeutic outcome. The concept of vaccination has today paved a new path for treatment of complex disease like cancer, the cure for which is still highly limited to conventional therapeutics. However, with the emergence of immunotherapy, the cancer therapy segment has also advanced to a whole new level.

The application of the concept of vaccination to complex disease like cancer has grabbed immense attention in both academia and industries. Multiple clinical studies have shown that an ideal vaccine for cancer is in fact possible with the help of modern immunotherapy and advanced therapy. However, the study has further being extended with rigorous effort being put in the development of personalized cancer vaccine which are anticipated to have even better therapeutic outcome than cancer vaccines.

Owing to the advancement in science and technology along with the emergence of advanced computing, few cancer vaccines like cervarix for cervical cancer and provenge for prostate cancer have already entered the market. Both the vaccines are therapeutic vaccines which have shown excellent outcome in the clinical trials. The emergence of genome sequencing and ability to identify and target neo-antigens has led to the possibility of these vaccines being developed for many types of cancer in a more personalized form in the future.

The cancer vaccine pipeline is expected to increase at tremendous rates in coming years. As large numbers of cancer vaccines are entering in various phases of clinical trials, due to which cancer market will soon observe a boost. However, the novelty of cancer vaccines makes it difficult for the standardization of clinical trials, because the criteria’s required to quantify its effectiveness are not completely discovered, this cause loss of valuable time. Moreover, the present day methods are standardized for conventional cancer therapeutic methods like chemotherapy, radiotherapy and surgery, which are not applicable for cancer vaccines due to their different mode of actions. In near future, researchers will find the solution for this problem and it will decrease the winding time.

Report Highlights

Global Cancer Vaccine market Opportunity: US$ 15 Billion Opportunity Personalized Cancer Vaccine: The Next Growth Frontier Global Cancer Vaccine Clinical insight by Indication & Phase of Development Global Cancer Vaccine Pipeline: 369 Cancer Vaccines Marketed Cancer Vaccines: 17 Cancer Vaccines Maximum Vaccines in Pipeline for Brain & Breast Cancer: 43 Cancer Vaccines Regulatory Landscape

Companies Profiled

Advaxis AVAX Technologies Dendreon Corporation Galena Biopharma GlaxoSmithKline ImmunoCellular Therapeutics ImmunoGen Inovio Pharmaceuticals KAEL-GemVax Liponova MedImmune Merck NeoStem Oncology NewLink Genetics Northwest Biotherapeutics Novartis Peregrine Pharmaceuticals Recombio Roche Roche Seattle Genetics Valeant Pharmaceuticals

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/b7k7wh/the_global_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005690/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials,Cancer Vaccines



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 02:56 PM/DISC: 09/17/2018 02:56 PM


Update hourly